Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEBBLES: EpiCeram for Prevention of Eczema and Food Allergy
NCT03667651Phase 3Active, not recruiting
- Sponsor
- University of Melbourne
- Start
- Mar 2018
- Primary completion
- May 2027
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of EpiCeram in Eczema and food allergy (2 arms), sponsored by University of Melbourne. Primary endpoints: Presence of eczema at 12 months and Confirmed diagnosis of food allergy at 12 months. Started Mar 2018; status: active, not recruiting.
02
Drugs
EpiCeram
03
Conditions
Eczemafood allergy
Beyond the preview
Go deeper on NCT03667651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667651.